Peer Review History
| Original SubmissionApril 11, 2026 |
|---|
|
-->PONE-D-26-17844-->-->The burden and epidemiology of orofacial cleft and its socioeconomic associates in Iran from 1990 to 2023-->-->PLOS One Dear Dr. Bakhtiari, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Jul 01 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:-->
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only the individual author can complete the verification step; PLOS staff cannot verify ORCID iDs on behalf of authors. We look forward to receiving your revised manuscript. Kind regards, Omid Beiki, M.D., Ph.D. Academic Editor PLOS One Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1.Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 2. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. 3. Please note that funding information should not appear in any section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. Please remove any funding-related text from the manuscript. 4. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information. 5. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. [Note: HTML markup is below. Please do not edit.] Reviewer's Responses to Questions -->Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. --> Reviewer #1: Partly Reviewer #2: Yes ********** -->2. Has the statistical analysis been performed appropriately and rigorously? --> Reviewer #1: No Reviewer #2: Yes ********** -->3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.--> Reviewer #1: Yes Reviewer #2: Yes ********** -->4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.--> Reviewer #1: Yes Reviewer #2: Yes ********** -->5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)--> Reviewer #1: Title The title appropriately identifies the topic and geographical scope but does not indicate that the study relies entirely on GBD-derived modeled estimates. The phrase “socioeconomic associates” is vague and potentially misleading, as the analysis is limited to ecological SDI correlations rather than evaluation of socioeconomic determinants. Abstract The abstract lacks sufficient methodological detail regarding how GBD estimates were obtained and analyzed. Statements describing reductions as significant require clarification regarding statistical criteria. The conclusion overstates policy implications related to maternal health programs despite no direct analysis of maternal risk factors. Introduction The rationale for conducting this study in Iran requires stronger justification beyond updating epidemiological estimates. The manuscript does not sufficiently explain the remaining knowledge gap considering multiple previous GBD-based OFC burden studies. The introduction lacks discussion regarding important distinctions between OFC subtypes and their epidemiologic implications. Methods Definition of Condition Combining all OFC phenotypes into a single category limits epidemiological interpretation because cleft palate and cleft lip with or without palate have different biological and clinical characteristics. The assumption of equal distribution among sequelae requires stronger justification because it may influence DALY estimation. Mathematical Modeling The manuscript reproduces GBD methodology but does not adequately clarify whether authors independently modeled estimates or extracted pre-generated outputs. GBD assumptions are described extensively but their implications for interpretation in the Iranian setting are not discussed. Statistical Analysis Details regarding smoothing spline models remain insufficient. Model assumptions, smoothing parameters, and analytical procedures are not adequately described. The manuscript lacks reproducibility details including extraction parameters and analytical workflow. Results Comparisons among Iran, MENA, and global estimates remain descriptive without formal comparative analyses. Provincial variation is described extensively but remains observational and lacks spatial analytical methods. Age-related prevalence findings require cautious interpretation because prevalence in congenital conditions accumulates over time and may not reflect disease biology. The higher DALY burden among females under five years is reported without exploration of possible explanations. Discussion Several interpretations attribute declining burden to improved surgical care, healthcare access, neonatal support, and health-system improvements despite these variables not being directly analyzed. Explanations regarding referral patterns, healthcare inequalities, and reporting differences remain speculative. The discussion occasionally shifts from epidemiologic interpretation toward causal inference unsupported by presented data. The markedly larger reduction in DALYs observed in Iran relative to global estimates warrants deeper discussion. Ecological SDI findings should be interpreted cautiously to avoid ecological fallacy. Limitations Important limitations are incompletely addressed. The study should explicitly discuss reliance on modeled rather than observed data. Limitations related to sparse provincial data, ecological analysis, inability to evaluate subtype-specific patterns, and inability to distinguish syndromic and non-syndromic OFCs should be acknowledged. Conclusion The conclusion contains policy recommendations that extend beyond the presented analyses. Statements regarding prevention strategies and healthcare interventions should be more closely aligned with observed epidemiological findings. Figures and Tables Figure 1 is visually crowded and difficult to interpret because of simultaneous presentation of multiple variables. Figure 2 uses dual-axis presentation that complicates interpretation. Figure 3 contains substantial visual overlap that limits readability. Several figures emphasize descriptive visualization but provide limited analytical insight. Table terminology such as “Pcs in rate” should be clearly defined. References References are generally appropriate; however, the manuscript relies heavily on prior GBD-based publications, particularly References 4, 8, 10, 11, 12, and 13, which limits broader contextualization beyond burden-database analyses. Greater discussion of how the present findings compare with and extend previous OFC burden studies, particularly References 4, 8, and 13, would strengthen the manuscript and better clarify its contribution. Additional comparison with Iranian epidemiological literature, including References 5, 6, 7, 14, 18, and 19, would improve interpretation and help contextualize similarities and discrepancies in prevalence estimates, geographic variation, and temporal trends. Reviewer #2: 1. The manuscript mainly reproduces descriptive estimates from the GBD 2023 platform without providing substantial methodological novelty or additional analytical depth. Since the study relies entirely on secondary modeled data, the scientific contribution would be strengthened by including more original interpretation, validation with national registry data, or deeper exploration of factors potentially driving provincial disparities. 2. The interpretation of temporal trends appears somewhat overstated given the nature of GBD estimates. The reported declines in incidence, DALYs, and mortality may partly reflect changes in modeling methods, reporting completeness, survival, and healthcare access rather than true reductions in disease occurrence alone. The discussion should acknowledge this more carefully to avoid causal over-interpretation. 3. The manuscript repeatedly attributes provincial differences to factors such as prenatal screening, consanguinity, maternal exposures, or healthcare access; however, these variables were not directly analyzed in the study. While these explanations are plausible, they remain speculative within the current design and should be presented more cautiously unless supported by province-level evidence. 4. The use of SDI analysis is relevant, but the interpretation remains descriptive. The manuscript reports an inverse association between SDI and DALY burden, yet no quantitative assessment of correlation strength, model fit, or sensitivity analysis is provided beyond smoothing splines. Additional analytical detail would help readers better understand the robustness and public health significance of this association. 5. The epidemiological interpretation of prevalence requires clarification. The manuscript reports stable prevalence despite marked declines in DALYs and mortality, but this important finding is only briefly discussed. Greater attention should be given to how improved survival, earlier surgical interventions, and long-term survivorship may contribute to persistent prevalence despite declining disability burden. 6. The study combines all orofacial cleft subtypes into a single category, which may mask important epidemiological and clinical differences between cleft lip, cleft palate, and combined cleft lip/palate. Since these subtypes differ in risk factors, severity, management, and outcomes, the absence of subtype-specific analyses limits the clinical interpretability of the findings. 7. Several conclusions extend beyond what can be directly inferred from GBD data alone. Recommendations regarding maternal health programs, neonatal care expansion, and preventive strategies are reasonable, but the study itself does not evaluate intervention effectiveness or healthcare quality indicators. The conclusions should therefore remain more closely aligned with the descriptive nature of the analysis. 8. The manuscript would benefit from a more critical discussion of the limitations of GBD subnational estimates. Provincial-level estimates in settings with incomplete surveillance may carry substantial uncertainty, especially for congenital anomalies. Although uncertainty intervals are reported, the implications of sparse primary data and possible under-ascertainment should be discussed in greater depth. ********** -->6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.--> Reviewer #1: No Reviewer #2: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications.
|
| Revision 1 |
|
-->PONE-D-26-17844R1-->-->The burden and epidemiology of orofacial clefts in Iran from 1990 to 2023: a Global Burden of Disease study with subnational socio-demographic index analysis-->-->PLOS One Dear Dr. Bakhtiari, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Jul 27 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:-->
--> If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only the individual author can complete the verification step; PLOS staff cannot verify ORCID iDs on behalf of authors. We look forward to receiving your revised manuscript. Kind regards, Omid Beiki, M.D., Ph.D. Academic Editor PLOS One Journal Requirements: 1. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. 2. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. [Note: HTML markup is below. Please do not edit.] Reviewer's Responses to Questions -->Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.--> Reviewer #1: All comments have been addressed Reviewer #2: (No Response) ********** -->2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. --> Reviewer #1: Yes Reviewer #2: Yes ********** -->3. Has the statistical analysis been performed appropriately and rigorously? --> Reviewer #1: Yes Reviewer #2: Yes ********** -->4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.--> Reviewer #1: Yes Reviewer #2: (No Response) ********** -->5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.--> Reviewer #1: Yes Reviewer #2: Yes ********** -->6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)--> Reviewer #1: The authors have addressed my comments satisfactorily and significantly improved the manuscript. The revised version is clearer, more balanced, and methodologically transparent. Reviewer #2: 1. The manuscript should clearly distinguish whether the authors conducted any independent modeling or simply analyzed pre-existing IHME/GBD outputs. As currently written, this distinction is blurred. It needs to explicitly state that no new primary DisMod-MR 2.1 modeling was performed, and that the work is based on descriptive analysis of extracted GBD data rather than reproduction of the original modeling framework. 2. The aggregation of all orofacial clefts (ICD-10 Q35–Q37) into a single category conceals meaningful clinical and biological differences between subtypes such as cleft palate and cleft lip with or without cleft palate. While this grouping may be constrained by the structure of available GBD data, the manuscript should acknowledge that it reduces clinical granularity and may limit the interpretability and real-world applicability of burden estimates. 3. The use of smoothing splines to model the relationship between SDI and burden metrics is not sufficiently described. Key details such as smoothing parameters, degrees of freedom, and model fit assessment are missing. The analysis should be explicitly framed as an exploratory, descriptive approach rather than inferential modeling, with clearer justification of how curve smoothness was selected to avoid the impression of arbitrary fitting. 4. The observed inverse association between provincial SDI and DALYs is interpreted too strongly in places, risking ecological fallacy. Because the data are aggregated at the provincial level, these findings should not be extended to individual-level socioeconomic risk. The results should be framed strictly as area-level patterns rather than implying individual-level relationships. 5. The manuscript highlights stable prevalence over time alongside a substantial reduction in DALYs and mortality, but this pattern is not well explained. A clearer interpretation is needed, likely involving improved survival, better long-term management, and the accumulation of treated individuals who continue to live with the condition, which maintains prevalence even as severity and mortality decline. 6. Several causal explanations for declining DALYs and mortality are stated too definitively. Since the GBD dataset does not directly measure healthcare access, prenatal screening, or underlying risk factors, these should be reframed as possible contributing hypotheses rather than confirmed drivers of change. 7. The policy recommendations extend beyond what can be justified by a descriptive epidemiological analysis. Specific clinical or preventive interventions should be avoided. Instead, conclusions should focus on higher-level public health implications such as strengthening congenital anomaly surveillance systems, improving registry completeness, and supporting broad resource allocation and health system planning. ********** -->7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.--> Reviewer #1: No Reviewer #2: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications. --> |
| Revision 2 |
|
The burden and epidemiology of orofacial clefts in Iran from 1990 to 2023: a Global Burden of Disease study with subnational socio-demographic index analysis PONE-D-26-17844R2 Dear Dr. Bakhtiari, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Omid Beiki, M.D., Ph.D. Academic Editor PLOS One Additional Editor Comments (optional): Reviewers' comments: |
| Formally Accepted |
|
PONE-D-26-17844R2 PLOS One Dear Dr. Bakhtiari, I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team. At this stage, our production department will prepare your paper for publication. This includes ensuring the following: * All references, tables, and figures are properly cited * All relevant supporting information is included in the manuscript submission, * There are no issues that prevent the paper from being properly typeset You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps. Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing. If we can help with anything else, please email us at customercare@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Omid Beiki Academic Editor PLOS One |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .